Phase 1 study of MLN8054, a selective inhibitor of Aurora A kinase in patients with advanced solid tumors

Author： Dees E.   Infante Jeffrey   Cohen Roger   O’Neil Bert   Jones Suzanne   Mehren Margaret   Danaee Hadi   Lee Yih   Ecsedy Jeffrey   Manfredi Mark   Galvin Katherine   Stringer Bradley   Liu Hua   Eton Omar   Fingert Howard   Burris Howard  

Publisher： Springer Publishing Company

ISSN： 0344-5704

Source： Cancer Chemotherapy and Pharmacology, Vol.67, Iss.4, 2011-04, pp. : 945-954

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Phase 1 study of the investigational, oral angiogenesis inhibitor motesanib in Japanese patients with advanced solid tumors

By Fujisaka Yasuhito   Yamada Yasuhide   Yamamoto Noboru   Shimizu Toshio   Fujiwara Yutaka   Yamada Kazuhiko   Tamura Tomohide   Watanabe Hiroyuki   Sun Yu-Nien   Bass Michael   Seki Mitsuo  

Cancer Chemotherapy and Pharmacology, Vol. 66, Iss. 5, 2010-10 ,pp. : 935-943

Springer Publishing Company

Access to resources Recommend Favorite

Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors

By Sausville Edward   LoRusso Patricia   Carducci Michael   Carter Judith   Quinn Mary   Malburg Lisa   Azad Nilofer   Cosgrove David   Knight Richard   Barker Peter   Zabludoff Sonya   Agbo Felix   Oakes Patricia   Senderowicz Adrian  

Cancer Chemotherapy and Pharmacology, Vol. 73, Iss. 3, 2014-03 ,pp. : 539-549

Springer Publishing Company

Access to resources Recommend Favorite

A phase I study of the safety and pharmacokinetics of edotecarin (J-107088), a novel topoisomerase I inhibitor, in patients with advanced solid tumors

By Hurwitz Herbert   Cohen Roger   McGovren J.   Hirawat Samit   Petros William   Natsumeda Yutaka   Yoshinari Tomoko  

Cancer Chemotherapy and Pharmacology, Vol. 59, Iss. 1, 2007-01 ,pp. : 139-147

Springer Publishing Company

Access to resources Recommend Favorite

Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative and inhibitor of tubulin polymerization, which was administered to patients with advanced solid tumors on days 1 and 8 in 3-week courses

By Tamura Kenji   Nakagawa Kazuhiko   Kurata Takayasu   Satoh Taroh   Nogami Toshiji   Takeda Koji   Mitsuoka Shigeki   Yoshimura Naruo   Kudoh Shinzoh   Negoro Shunichi   Fukuoka Masahiro  

Cancer Chemotherapy and Pharmacology, Vol. 60, Iss. 2, 2007-07 ,pp. : 285-293

Springer Publishing Company

Access to resources Recommend Favorite

Phase 1 Results From a Study of Romidepsin in Combination With Gemcitabine in Patients With Advanced Solid Tumors

By Jones Suzanne F.   Infante Jeffrey R.   Spigel David R.   Peacock Nancy W.   Thompson Dana S.   Greco F. Anthony   McCulloch William   Burris III Howard A.  

Cancer Investigation, Vol. 30, Iss. 6, 2012-06 ,pp. : 481-486

Informa Healthcare

Access to resources Recommend Favorite